UBS Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $182M | Buy |
756,865
+399,662
| +112% | +$87.6M | 0.02% | 722 |
|
|
2026
Q1 | $67.5M | Sell |
357,203
-115,749
| -24% | -$20.2M | 0.01% | 1350 |
|
|
2025
Q4 | $80.4M | Buy |
472,952
+18,485
| +4% | +$2.83M | 0.01% | 1185 |
|
|
2025
Q3 | $59.9M | Buy |
454,467
+63,246
| +16% | +$7.59M | 0.01% | 1443 |
|
|
2025
Q2 | $41.5M | Sell |
391,221
-25,789
| -6% | -$2.8M | 0.01% | 1684 |
|
|
2025
Q1 | $51.8M | Buy |
417,010
+86,167
| +26% | +$11.2M | 0.01% | 1456 |
|
|
2024
Q4 | $40.7M | Buy |
330,843
+167,105
| +102% | +$19.7M | 0.01% | 1633 |
|
|
2024
Q3 | $18.2M | Buy |
163,738
+30,949
| +23% | +$3.39M | ﹤0.01% | 1902 |
|
|
2024
Q2 | $14.2M | Sell |
132,789
-31,611
| -19% | -$3.48M | ﹤0.01% | 1954 |
|
|
2024
Q1 | $19.8M | Sell |
164,400
-8,547
| -5% | -$1.05M | ﹤0.01% | 1692 |
|
|
2023
Q4 | $21.3M | Buy |
172,947
+26,844
| +18% | +$3.35M | 0.01% | 1546 |
|
|
2023
Q3 | $18.9M | Sell |
146,103
-13,622
| -9% | -$1.82M | 0.01% | 1525 |
|
|
2023
Q2 | $19.8M | Sell |
159,725
-13,972
| -8% | -$1.88M | 0.01% | 1458 |
|
|
2023
Q1 | $25.4M | Sell |
173,697
-71,066
| -29% | -$10.5M | 0.01% | 1210 |
|
|
2022
Q4 | $39M | Buy |
244,763
+84,347
| +53% | +$12.4M | 0.01% | 956 |
|
|
2022
Q3 | $21.4M | Buy |
160,416
+6,540
| +4% | +$994K | 0.01% | 1228 |
|
|
2022
Q2 | $24M | Sell |
153,876
-15,198
| -9% | -$2.34M | 0.01% | 1190 |
|
|
2022
Q1 | $26.3M | Sell |
169,074
-14,173
| -8% | -$2.06M | 0.01% | 1234 |
|
|
2021
Q4 | $23.3M | Sell |
183,247
-3,307
| -2% | -$435K | 0.01% | 1472 |
|
|
2021
Q3 | $24.3M | Buy |
186,554
+9,102
| +5% | +$1.38M | 0.01% | 1350 |
|
|
2021
Q2 | $31.5M | Buy |
177,452
+45,453
| +34% | +$7.87M | 0.01% | 1131 |
|
|
2021
Q1 | $21.7M | Sell |
131,999
-35,925
| -21% | -$5.91M | 0.01% | 1392 |
|
|
2020
Q4 | $27.7M | Sell |
167,924
-70,255
| -29% | -$10.5M | 0.01% | 1135 |
|
|
2020
Q3 | $34M | Sell |
238,179
-11,756
| -5% | -$1.46M | 0.01% | 860 |
|
|
2020
Q2 | $27.6M | Sell |
249,935
-41,680
| -14% | -$4.61M | 0.01% | 901 |
|
|
2020
Q1 | $29.1M | Buy |
291,615
+23,157
| +9% | +$2.99M | 0.01% | 792 |
|
|
2019
Q4 | $40.1M | Sell |
268,458
-167,067
| -38% | -$22.7M | 0.01% | 900 |
|
|
2019
Q3 | $55.8M | Buy |
435,525
+6,323
| +1% | +$848K | 0.02% | 633 |
|
|
2019
Q2 | $61.2M | Sell |
429,202
-80,094
| -16% | -$10.8M | 0.02% | 578 |
|
|
2019
Q1 | $72.8M | Buy |
509,296
+119,928
| +31% | +$15.6M | 0.03% | 473 |
|
|
2018
Q4 | $48.3M | Sell |
389,368
-56,114
| -13% | -$8.32M | 0.02% | 607 |
|
|
2018
Q3 | $74.9M | Buy |
445,482
+42,132
| +10% | +$7.25M | 0.03% | 503 |
|
|
2018
Q2 | $69.5M | Buy |
403,350
+23,550
| +6% | +$3.85M | 0.03% | 519 |
|
|
2018
Q1 | $57.3M | Buy |
379,800
+10,256
| +3% | +$1.5M | 0.02% | 578 |
|
|
2017
Q4 | $49.8M | Buy |
369,544
+69,097
| +23% | +$9.58M | 0.02% | 676 |
|
|
2017
Q3 | $43.9M | Sell |
300,447
-13,185
| -4% | -$1.99M | 0.02% | 659 |
|
|
2017
Q2 | $48.8M | Sell |
313,632
-24,801
| -7% | -$3.79M | 0.03% | 570 |
|
|
2017
Q1 | $49.1M | Buy |
338,433
+52,532
| +18% | +$6.84M | 0.03% | 557 |
|
|
2016
Q4 | $31.2M | Buy |
285,901
+68,268
| +31% | +$7.6M | 0.02% | 765 |
|
|
2016
Q3 | $26.4M | Buy |
217,633
+17,676
| +9% | +$2.38M | 0.02% | 806 |
|
|
2016
Q2 | $28.3M | Buy |
199,957
+52,594
| +36% | +$7.75M | 0.02% | 738 |
|
|
2016
Q1 | $19.2M | Sell |
147,363
-11,325
| -7% | -$1.41M | 0.01% | 904 |
|
|
2015
Q4 | $22.3M | Sell |
158,688
-24,727
| -13% | -$3.43M | 0.01% | 889 |
|
|
2015
Q3 | $24.4M | Buy |
183,415
+29,133
| +19% | +$5.02M | 0.02% | 772 |
|
|
2015
Q2 | $27.2M | Buy |
154,282
+30,766
| +25% | +$5.53M | 0.02% | 790 |
|
|
2015
Q1 | $21.3M | Sell |
123,516
-42,042
| -25% | -$7.22M | 0.01% | 912 |
|
|
2014
Q4 | $27.1M | Buy |
+165,558
| New | +$27.5M | 0.02% | 824 |
|
Other funds holding JAZZ
UBS Group's JAZZ Position: Q2 2026 in Review
UBS Group increased its Jazz Pharmaceuticals (JAZZ) stake by 112% in Q2 2026, buying an estimated $87.6M and bringing the position to 756,865 shares worth $182M. The position accounts for 0.02% of the portfolio, ranked #722.
UBS Group first reported a position in JAZZ in Q4 2014 and has held it in 47 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- UBS Group held 756,865 shares of Jazz Pharmaceuticals worth $182M as of Q2 2026.
- UBS Group bought 399,662 Jazz Pharmaceuticals shares in Q2 2026, an estimated $87.6M.
- Jazz Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #722 holding.
- UBS Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.